Aquinox (AQXP) Announces Third Quarter 2016 Financial Results
11/9/2016 7:44:55 AM
VANCOUVER, British Columbia, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update and reported financial results for the third quarter ending September 30, 2016.
“In September we commenced enrollment in the LEADERSHIP 301 Phase 3 clinical trial with AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS) and we are continuing to add sites and jurisdictions to the trial as planned,” said David Main, President & CEO of Aquinox. “Our objective remains to release top-line data from this first Phase 3 trial in the fourth quarter of 2017 and we will provide an enrollment update when we release year-end 2016 financial results in early 2017. Our recent financing, together with cash on-hand, positions us well to advance AQX-1125 and broaden our clinical and research activities.”
comments powered by